Antibiotic lock therapy for catheter-related bloodstream infections in pediatric hemato-oncology: a retrospective analysis Authors: Besarta Kaçabeti, Remziye Semerci Şahin, Pınar Taşpınar, Gülcan Erbaş, Serap Karaman, Zeynep Karakaş, Ayper Somer, Selda Hançerli, Gülşah Tanyıldız Published: 2026 ABSTRACT AbstractPurposeThis study aims to comprehensively evaluate the efficacy and safety of Antibiotic Lock Therapy (ALT) in pediatric patients and to better clarify its role in catheter management.MethodsThis retrospective single-center study was conducted between October 2021 and October 2024. Of 53 eligible patients, 47 received ALT and constituted the primary analysis population for treatment outcomes; 6 patients underwent immediate catheter removal without ALT and were excluded from the ALT efficacy analysis. Demographic, clinical, and microbiological data from all patients were collected.ResultsA total of 70 catheter-related bloodstream infection (CRBSI) episodes were identified among 47 patients, corresponding to an incidence rate of 12.79 per 1,000 catheter-days. The most frequently isolated pathogens were coagulase-negative staphylococci (CoNS), followed by gram-positive bacilli and Klebsiella spp. Antibiotic Lock Therapy (ALT) was administered to 47 patients and was successful in 70.2% of these cases (33/47) (p = 0.038). Among patients who did not receive ALT and required catheter removal, Klebsiella spp. and methicillin-resistant CoNS (MRCoNS) were the predominant organisms associated with sepsis and infection. In patients requiring catheter removal despite receiving ALT, gram-negative organisms were the most common pathogens, followed by gram-positive bacilli. Notably, infections most frequently developed between days 11 and 45 of catheter use, indicating a critical high-risk window for catheter-related infections.ConclusionCatheter-related infections remain a significant clinical challenge in pediatric hematology–oncology patients. Our findings suggest that ALT was associated with catheter retention in a considerable proportion of patients; however, given the retrospective design and potential for confounding by indication, this observation should be interpreted cautiously rather than as a definitive efficacy claim. The identification of a high-risk period between days 11 and 45 may support closer monitoring and earlier intervention. Further prospective studies with standardized selection criteria are required to validate and standardize the use of ALT in this vulnerable population.Keywords: Central venous catheter, Catheter-related bloodstream infection, Antibiotic lock therapy, Catheter care, Pediatric patients Introduction Advances in diagnostic methods, multimodal therapies, and supportive care have substantially improved survival in pediatric oncology, transforming many childhood cancers into chronic conditions requiring prolonged treatment and follow-up [1]. Although childhood cancer is relatively rare, it remains one of the leading causes of disease-related mortality among children worldwide. Advances in diagnosis and treatment have increased 5-year survival rates to over 80% in most high-income countries; however, more than 80% of the global childhood cancer burden occurs in low- and middle-income countries, where survival outcomes remain substantially poorer due to inequalities in access to healthcare and supportive services. Lymphohematopoietic malignancies account for approximately 40% of pediatric cancers, followed by central nervous system tumors and embryonal malignancies [2]. These conditions necessitate intensive treatment protocols, making reliable long-term vascular access essential. Central venous catheters (CVCs) are integral to pediatric oncology care, enabling administration of chemotherapy, parenteral nutrition, and blood products, as well as repeated blood sampling. However, their use is associated with significant complications, particularly catheter-related bloodstream infections (CRBSIs), which contribute to increased morbidity, mortality, and healthcare costs in immunocompromised patients [3–6]. CRBSIs remain a major clinical concern, with variable incidence and outcomes. Management is complicated by the formation of intraluminal biofilms, which markedly reduce the effectiveness of systemic antibiotic therapy and often necessitate catheter removal [7–10]. Systemic antibiotics have limited penetration into the intraluminal biofilm matrix, where bacteria exist in a sessile state with reduced metabolic activity, which protects them from both host immune responses and antimicrobial agents and contributes to persistent infection despite appropriate systemic therapy [7–10]. While catheter removal can resolve infection, it may be undesirable in pediatric hemato-oncology patients due to limited vascular access and the need for ongoing intensive therapy. ALT has emerged as an adjunctive strategy to eradicate biofilm-associated microorganisms by instilling high-concentration antimicrobial solutions into the catheter lumen. Its use, particularly in hemodynamically stable patients without tunnel or exit-site infection, is supported by clinical guidelines, including the 2009 Infectious Diseases Society of America (IDSA) guideline for CRBSI management [11]. However, evidence regarding the effectiveness of ALT in pediatric hemato-oncology populations remains limited and heterogeneous, with variability in patient selection and treatment protocols. Therefore, further data are needed to better define the role of ALT in this high-risk group. The aim of this study is to describe outcomes associated with antibiotic lock therapy in pediatric hemato-oncology patients with CRBSI, with a particular focus on catheter salvage. Additionally, we describe the microbiological characteristics of CRBSI episodes in this cohort. Methods Study design This study was a single-center, retrospective, observational study. The primary aim was to evaluate the effectiveness of ALT in pediatric patients with hematologic or oncologic diagnoses who developed catheter-related bloodstream infections, to examine the relationship between different CVCs types and infection occurrence, and to highlight the importance of catheter care in the prevention of these infections. Study setting The study was conducted in the Pediatric Hematology and Oncology Division of the Department of Child Health and Diseases, Istanbul University Faculty of Medicine, a tertiary university hospital and referral center for pediatric hematology–oncology patients. The unit provides comprehensive diagnostic and therapeutic services, including intensive chemotherapy, hematopoietic stem cell transplantation, parenteral nutrition, and supportive care. Central venous catheters and implanted port catheters are routinely used in this setting to ensure reliable long-term venous access for children requiring prolonged treatment. Study sample and eligibility criteria The study population consisted of pediatric patients followed in the Pediatric Hematology and Oncology Division between October 2021 and October 2024. A retrospective review identified 65 patients with hematologic or oncologic diagnoses who had central venous access during the study period. Patients were eligible for inclusion if they were aged 0–18 years, had a confirmed hematologic or oncologic diagnosis, were receiving active treatment, and had a CVCs or implanted port with at least one episode of catheter-related microbial growth consistent with infection. Patients were excluded if they were older than 18 years, did not have a hematologic or oncologic diagnosis, lacked central venous access, were not receiving active oncologic treatment during the study period, or had no documented catheter-related microbial growth. Patients with suspected tunnel infection were not excluded from the study population; however, they were not considered eligible for ALT and were managed according to standard clinical practice, typically involving catheter removal. Of the 65 patients initially identified, 12 were excluded because no documented catheter-related microbial growth was present. The final study sample consisted of 53 pediatric patients who met all eligibility criteria. The transition from the initial screening population to the final study sample and intervention subgroup is summarized in the patient flow diagram (Fig. 1). Flow diagram for patient selection group allocation CRBSI diagnostic criteria In this study, CRBSI was defined according to the 2009 IDSA clinical practice guidelines. A case was classified as CRBSI when at least one of the following criteria was met: (1) isolation of the same organism from both a catheter-drawn blood culture and a peripheral blood culture in a patient with clinical signs of infection (fever > 38 °C, chills, or hypotension) with no other identifiable source; (2) a differential time to positivity (DTP) of ≥ 2 h, defined as the catheter-drawn blood culture turning positive at least two hours earlier than the simultaneously drawn peripheral blood culture; or (3) catheter-tip culture yielding ≥ 15 colony-forming units of the same organism identified in blood cultures, when catheter removal was performed. Contamination was distinguished from true CRBSI based on clinical context, culture results, and the treating clinician’s assessment. Single positive blood cultures for low-virulence organisms (e.g., coagulase-negative staphylococci) were considered contaminants unless corroborated by a second positive culture from a separate draw and accompanied by compatible clinical signs. Colonization was differentiated from infection by the absence of systemic signs of infection and by positive cultures from the catheter tip or hub only, without concurrent positive peripheral blood cultures. Blood cultures were obtained simultaneously from each lumen of the central venous catheter and from a peripheral vein at the time of fever evaluation. Each sample consisted of at least 2 mL of blood. Culture results were interpreted by the clinical microbiology laboratory using automated continuous-monitoring blood culture systems, and time-to-positivity was recorded for all samples to facilitate DTP analysis. In a subset of cases in which catheter-tip culture was unavailable due to the decision to retain the catheter, diagnosis was based on clinical presentation and blood culture results, interpreted in accordance with IDSA criteria. In these cases, DTP was the primary microbiological criterion used when simultaneous catheter and peripheral cultures were obtained. Standard central venous catheter care Central venous catheter care was performed in accordance with standard international guidelines, including recommendations from the Centers for Disease Control and Prevention, the Infusion Nurses Society, and the Infectious Diseases Society of America. No institutional deviations from these standards were in place during the study period. Briefly, care practices included strict hand hygiene, aseptic non-touch technique, chlorhexidine-based hub disinfection, and adherence to recommended flushing and dressing-change intervals. Patient and caregiver education on catheter hygiene was provided as part of routine care. Lock therapy procedure In our hospital, when a patient with a CVCs develops fever without an identifiable infectious focus, defined as a body temperature > 37.5 °C persisting for at least two hours or a single measurement above 38 °C, nursing care follows a standardized infection evaluation procedure. As part of this protocol, the nurse obtains blood cultures from the peripheral vein and each catheter lumen, collecting at least 2 mL from each site. Additionally, specimens are taken from any clinically suspicious areas to help identify a potential infection source. All patients receive systemic antibiotic therapy in conjunction with ALT, and nurses ensure these treatments are administered in strict accordance with the Infectious Diseases Society of America (IDSA) guidelines. ALT solutions are replaced every 24–48 h, depending on the characteristics of the isolated microorganism. The total duration of therapy ranges between 7 and 14 days, individualized according to pathogen-specific requirements. Throughout this period, nurses monitor treatment timing, ensure proper lock dwell and replacement, and adjust care to align with microorganism-specific clinical recommendations. The decision to initiate ALT versus proceeding directly to catheter removal was made by the treating physician based on the following clinical criteria, consistent with IDSA recommendations. ALT was considered in hemodynamically stable patients with no evidence of tunnel or exit-site infection, catheter-related thrombosis, or infection caused by fungi or highly virulent organisms such as Staphylococcus aureus. Direct catheter removal was performed when any of these conditions were present, when the patient showed clinical deterioration despite adequate systemic antibiotic therapy, or when persistent bacteremia was documented. In all cases, treatment allocation reflected individualized clinical judgment integrating the patient’s hemodynamic status, pathogen identity, catheter functionality, and the clinical necessity of catheter preservation for ongoing treatment. Data collection This study was conducted in the Pediatric Hematology and Oncology Division of Istanbul Faculty of Medicine and was designed as a retrospective evaluation of lock therapy practices and central venous catheter care in pediatric hematology–oncology patients. A total of 53 patients were included based on data extracted from historical medical records. All information was systematically collected using a structured patient follow-up form (Form 1), which ensured standardized documentation of demographic and clinical characteristics, treatment processes, and details related to catheter use. Data sources included patient files, archival clinical documentation, and laboratory reports. These records were reviewed to obtain information on infection episodes, microbiological results, catheter type and duration, administered therapies, and clinical outcomes. As a retrospective study, no interventions were performed, and therefore, additional informed consent from patients or legal guardians was not required. All procedures were carried out in accordance with ethical principles and strict confidentiality standards. The Pediatric Hematology and Oncology Division of Istanbul Faculty of Medicine is a specialized tertiary center serving a large and diverse pediatric population, which strengthened the scope and scientific value of the dataset obtained for this study. Statistical analysis Statistical analyses were performed using SPSS version 22 (Statistical Package for the Social Sciences). Given the relatively small sample size, normality of continuous variables was assessed prior to analysis using the Shapiro-Wilk test. As most continuous variables were non-normally distributed, results are presented as medians and interquartile ranges (IQRs). Group comparisons for non-normally distributed continuous variables were performed using the Mann-Whitney U test for two independent groups and the Kruskal-Wallis test for three independent groups. For categorical variables, the chi-square test was applied when expected cell frequencies were adequate; Fisher’s exact test was substituted when any expected cell frequency was below five. A two-tailed p-value of < 0.05 was considered statistically significant for all analyses. Demographic, clinical, and ALT outcome analyses were performed at the patient level (n = 53). Microbiological characterization and infection timing analyses were conducted at the episode level (n = 70). When a patient experienced more than one CRBSI episode, each episode was recorded independently for analysis at the episode level. Within-patient non-independence was not formally adjusted for in the statistical models, which should be considered a limitation when interpreting episode-level findings. Demographic, clinical, and ALT outcome analyses were performed at the patient level (n = 53). Microbiological characterization and infection timing analyses were conducted at the episode level (n = 70). When a patient experienced more than one CRBSI episode, each episode was recorded independently for microbiological and temporal analyses. Within-patient non-independence was not formally adjusted for in the statistical models, which should be considered a limitation when interpreting episode-level findings. Ethical approval This study was approved by the Ethics Committee of Istanbul University, Istanbul Faculty of Medicine (Decision No: 10; Date: 24/05/2024). All procedures were conducted in accordance with institutional ethical standards and the principles of confidentiality applicable to retrospective research. The Ethics Committee of Istanbul University waived informed consent due to the study’s retrospective design and the use of anonymized data. All procedures were conducted in accordance with relevant guidelines and regulations, including the Declaration of Helsinki. Results A retrospective review was conducted on patients followed at the Division of Pediatric Hematology and Oncology, Istanbul University Faculty of Medicine, between October 2021 and October 2024. During this three-year period, data from pediatric patients diagnosed with hematological or oncological diseases who developed microbial growth associated with central venous catheter use were evaluated. Retrospective screening of the archive identified 53 patients who met the inclusion criteria. A total of 53 pediatric patients were evaluated for demographic and clinical features by catheter type. The mean age of the patients differed across catheter groups; however, the difference was not statistically significant (p = 0.180). Similarly, mean body weight (p = 0.058) and height (p = 0.054) did not differ significantly by catheter type. There was no statistically significant difference in the gender distribution of patients across catheter groups (p = 0.518), with males accounting for 58.5% of the overall sample. A significant difference in the distribution of diagnoses across catheter types was observed (χ² = 17.910, p = 0.006). Patients diagnosed with acute lymphoblastic leukemia (ALL) were more likely to have implantable ports or Vygon catheters, whereas patients with solid tumors predominantly used port catheters. Risk group status showed a significant association with catheter type (χ² = 10.771, p = 0.029). The majority of high-risk patients were observed across all catheter types, whereas low-risk patients were observed only within the port group. Neutropenia status did not differ significantly among catheter types (p = 0.781), and approximately half of the patients in each catheter type had neutropenia. Chemotherapy status was not significantly associated with catheter type (p = 0.422). More than half of the patients in each group were actively receiving chemotherapy at the time of microbial growth detection. Bone marrow transplantation history did not differ statistically across catheter types (p = 0.911), with the majority of patients having no prior transplantation. Peripheral growth of the infection was not significantly related to catheter type (p = 0.756). However, fever status showed a statistically significant difference (χ² = 6.891, p = 0.032). Fever was most commonly observed among patients with Vygon and port catheters (Table 1). Table 1Comparison of patient characteristics according to catheter type (n = 53)HickmanMean±SDMedian (IQR)VygonMean±SDMedian (IQR)PortMean±SDMedian (IQR)TotalMean±SDMedian (IQR)Test* P Age60.57±65.213-192 (33.5)92.85±67.212-204 (88.5)57.81±56.944-144 (41)77.05±65.712-204 (60)1.7720.180Weight20.42±16.574-55 (14.65)34.88±26.735-102 (23)19.3±14.974.5-46 (13.1)27.83±23.234-102 (19.6)3.0100.058Height100.14±36.9155-161 (89.5)125±36.2555-180 (120)100.9±33.0863-150 (89)113.43±37.2365-180 (115)3.0960.054 n % n % n % n %Gender1.3150.518 Male1071.401553.60654.503158.50 Female428.601346.40545.502241.50Diagnosis χ² p ALL642.901864.319.102547.2017.910 0.006 AML17.1027.1--35.70 Solid tumor428.60414.3981.801732.10 Lymphoma321.40414.319.10815.10Risk group Low----218.2023.8010.771 0.029 Medium214.30725.00--917.00 High1285.702175.00981.804279.20Having Neutropenia No750.001553.60763.602954.700.4940.781 Yes750.001346.40436.402445.30BMT treatment No1285.702589.301090.904788.700.1870.911 Yes214.30310.7019.10611.30Peripheral growth of the infection No1178.602071.40981.804075.500.5590.756 Yes321.40828.60218.201324.50Having fever Yes642.902382.10872.703769.806.891 0.032 Fever and other symptoms857.10517.90327.301630.20ALL Acute lymphoblastic leukemia, AML Acute myeloid leukemia, BMT Bone marrow transplantation, IQR Interquartile range, SD Standard deviation*Data are presented as mean ± standard deviation (SD) and median [interquartile range (IQR)] for continuous variables, and as n (%) for categorical variables. Comparisons between groups were performed using the independent samples t-test or Mann–Whitney U test for continuous variables, depending on data distribution, and the chi-square test or Fisher’s exact test for categorical variables, as appropriate. A p-value of < 0.05 was considered statistically significant Comparison of patient characteristics according to catheter type (n = 53) 60.57±65.21 3-192 (33.5) 92.85±67.21 2-204 (88.5) 57.81±56.94 4-144 (41) 77.05±65.71 2-204 (60) 20.42±16.57 4-55 (14.65) 34.88±26.73 5-102 (23) 19.3±14.97 4.5-46 (13.1) 27.83±23.23 4-102 (19.6) 100.14±36.91 55-161 (89.5) 125±36.25 55-180 (120) 100.9±33.08 63-150 (89) 113.43±37.23 65-180 (115) ALL Acute lymphoblastic leukemia, AML Acute myeloid leukemia, BMT Bone marrow transplantation, IQR Interquartile range, SD Standard deviation *Data are presented as mean ± standard deviation (SD) and median [interquartile range (IQR)] for continuous variables, and as n (%) for categorical variables. Comparisons between groups were performed using the independent samples t-test or Mann–Whitney U test for continuous variables, depending on data distribution, and the chi-square test or Fisher’s exact test for categorical variables, as appropriate. A p-value of < 0.05 was considered statistically significant Within the scope of this analysis, three patients who were evaluated as a precautionary measure and in whom no definitive microbial growth was detected were excluded. These patients were excluded to avoid potential misinterpretation of catheter-related culture intervals and to enhance the accuracy of the analyses. In the analysis of time to culture positivity (interval), the duration ranged from 1 to 420 days in patients with gram-positive growth, with a mean of 83.57 days (median: 30). In patients with gram-negative growth, the interval ranged from 1 to 300 days, with a mean of 60.29 days (median: 30) (Fig. 2). No statistically significant difference was observed between the gram-positive and gram-negative groups regarding culture intervals (p = 0.453). Evaluation of the distribution of culture results over the years demonstrated a predominance of gram-positive organisms. Gram-positive cocci, particularly coagulase-negative staphylococci (CoNS), were identified as the most frequently isolated pathogens, followed by gram-positive bacilli and Klebsiella spp. The catheter-associated infection rate was calculated as 12.79 per 1,000 catheter-days. The highest infection rate was observed in 2023, which is largely attributable to increased catheter utilization during that year. The data from our study indicate an increasing trend in catheter-related infection rates beginning in 2021, with rates peaking in 2023. A subsequent decline in infection rates was observed in 2024 (Fig. 3) Distribution of gram-positive and gram-negative isolates, catheter-associated infections by year Evaluation of microorganisms grown and neutropenia Of the 53 patients included in the study, 6 (11.32%) underwent immediate catheter removal without receiving ALT and were therefore excluded from the ALT efficacy analysis. The remaining 47 patients (88.68%) received ALT and constituted the primary analysis population for treatment outcomes. Among these 47 patients, catheter removal was still required in 14 cases (29.79%), whereas catheter use continued in 33 patients (70.21%; 33/47). A chi-square test of independence was performed to compare catheter retention rates between patients who received ALT (n = 47) and those who underwent immediate catheter removal without ALT (n = 6), using catheter retention (continued use vs. removal) as the outcome variable. This analysis demonstrated a statistically significant association between ALT receipt and catheter retention (χ² = 8.38, p = 0.038). However, as treatment allocation was not randomized and patients who underwent immediate catheter removal were clinically distinct from those who received ALT, this association should be interpreted as descriptive rather than causal (Fig. 4). Effect of antibiotic lock therapy on catheter removal status Table 2 presents a comparison of clinical and catheter-related characteristics between patients with gram-positive culture results and those with gram-negative culture results. Catheter dwell time did not differ significantly between the gram-positive and gram-negative groups (mean ± SD: 83.57 ± 110.87 vs. 60.29 ± 85.59 days, respectively; p = 0.453). Similarly, no statistically significant differences were observed between the groups in the time from catheter insertion to culture collection (p = 0.164), from catheter insertion to treatment initiation (p = 0.319), or from culture collection to treatment initiation (p = 0.246). Table 2Comparison of clinical and catheter-related characteristics between patients with gram-positive and gram-negative catheter-related culturesCharacteristicsGram Positive CultureMean ± SD Median (IQR)Gram NegativeCultureMean ± SD Median (IQR)TotalMean ± SD Median (IQR)Test* P Catheter-days83.57–110,871–420 (30)60.29 ± 85.591–300 (30)72.49 ± 100.551–420 (30)0.7560.453Time from catheter insertion to culture collection81.90 ± 100.530–413 (35)44.17 ± 61.471–247 (16)69.08 ± 90.330–413 (29)1.4130.164Time from catheter insertion to treatment initiation85.61 ± 103.280–414 (41)54.07 ± 68.8471–248 (29)76.29 ± 94.720–414 (37.5)1,0080.319Time from culture collection to treatment initiation2.16 ± 4.980–28 (1)7.61 ± 25.060–91 (1)3.77 ± 14.100–91 (1)−1.1760.246Using heparin n % n % n % χ² p With heparin2787.11184.63886.4 Without heparin412.9215.4613.6Antibiotic n % n % n % Teicoplanin2167.7--2147.721.067 < 0.001 Meropenem412.91076.91431.8 Linezolid26.517.736.8 Gentamicin13.217.724.5 Vancomycin39.717.749.1ANC < 5001030.3847.11836.05.8430.054 501–100013.0317.648.0 > 10002266.7635.32856.0Thrombocyte < 50,000515.2423.5918.04.4040.111 50,000–150,0001030.3952.91938.0 > 150,0001854.5423.52244.0TPN treatment No2884.81482.44284.00.0520.820 Yes515.2317.6816.0Risk of thrombus No2472.71058.83468.05.2560.072 Yes13,0423.5510.0Number of lumens One lumen2472.7952.93366.01.9570.162 Two lumens927.3847.11734.0Neutropenia No2266.7635.32856.04.482 0.034 Yes1133.31164.72244.0BMT treatment No3193.91482.44590.01.6740.196 Yes26.1317.6510.0ANC Absolute neutrophil count, BMT Bone marrow transplantation, IQR Interquartile range, SD Standard deviation, TPN Total parenteral nutrition*Data are presented as mean ± standard deviation (SD) and median [interquartile range (IQR)] for continuous variables, and as n (%) for categorical variables. Comparisons between groups were performed using the independent samples t-test or Mann–Whitney U test for continuous variables, depending on data distribution, and the chi-square test or Fisher’s exact test for categorical variables, as appropriate. A p-value of < 0.05 was considered statistically significant Comparison of clinical and catheter-related characteristics between patients with gram-positive and gram-negative catheter-related cultures 83.57–110,87 1–420 (30) 60.29 ± 85.59 1–300 (30) 72.49 ± 100.55 1–420 (30) 81.90 ± 100.53 0–413 (35) 44.17 ± 61.47 1–247 (16) 69.08 ± 90.33 0–413 (29) 85.61 ± 103.28 0–414 (41) 54.07 ± 68.847 1–248 (29) 76.29 ± 94.72 0–414 (37.5) 2.16 ± 4.98 0–28 (1) 7.61 ± 25.06 0–91 (1) 3.77 ± 14.10 0–91 (1) ANC Absolute neutrophil count, BMT Bone marrow transplantation, IQR Interquartile range, SD Standard deviation, TPN Total parenteral nutrition *Data are presented as mean ± standard deviation (SD) and median [interquartile range (IQR)] for continuous variables, and as n (%) for categorical variables. Comparisons between groups were performed using the independent samples t-test or Mann–Whitney U test for continuous variables, depending on data distribution, and the chi-square test or Fisher’s exact test for categorical variables, as appropriate. A p-value of < 0.05 was considered statistically significant The use of heparin was comparable between the two groups (p = 0.756). However, a statistically significant difference was observed in antibiotic use patterns (χ² = 21.067, p < 0.001), with meropenem being more frequently administered in patients with gram-negative infections, while teicoplanin was predominantly used among patients with gram-positive infections. Although the absolute neutrophil count (ANC) categories showed a trend toward significance (p = 0.054), neutropenia was significantly more frequent in the gram-negative group compared to the gram-positive group (p = 0.034). No significant differences were identified between the groups regarding platelet count categories, total parenteral nutrition (TPN) use, risk of thrombosis, number of catheter lumens, or bone marrow transplantation (BMT) status (all p > 0.05) (Table 2). Discussion This study aimed to comprehensively evaluate the efficacy and safety of ALT in pediatric hemato-oncology patients and to clarify its role in catheter management. In our retrospective cohort, the ALT success rate was 70.21% (33/47); however, this figure should be interpreted with caution due to patient selection bias. The six patients who underwent immediate catheter removal without ALT were excluded from this calculation, as they were deemed ineligible for catheter salvage due to higher illness severity, high-risk pathogens, or established contraindications. These patients likely represented the most clinically challenging cases in the cohort. Consequently, the reported success rate pertains exclusively to a pre-selected group of hemodynamically stable patients with relatively favorable clinical profiles, and may therefore overestimate the effectiveness of ALT when applied to an unselected population. This selection effect is inherent to retrospective observational studies and should be considered when generalizing these findings. Our findings are comparable with previously published pediatric data. In a single-center retrospective study including 37 children with catheter-related bloodstream infections, Signorino et al. [12] reported an overall ALT success rate of 67.6% (25/37), which is closely aligned with the success rate observed in our cohort. Similarly, in pediatric oncology and hematology patients, De Frutos Porras et al. [13] reported that among 58 CRBSI episodes, 41 of 58 (71%) cases treated with ALT achieved catheter preservation, whereas catheter removal was required in 13 of 41 (32%) patients receiving ALT compared with 12 of 17 (71%) patients who did not receive ALT, demonstrating a significant benefit of lock therapy in catheter retention. Pathogen-specific pediatric evidence further supports our results. In children with coagulase-negative staphylococcal central line–associated bloodstream infections, Ergenç et al. [14] reported an overall ALT success rate of 63% (12/19), with vancomycin-based ALT achieving success in 56% (5/9) and teicoplanin-based ALT in 62.5% (5/8). Although slightly lower than our observed rate, these findings support the effectiveness of ALT in pediatric patients with low-virulence pathogens. Evidence from neonatal populations also demonstrates favorable outcomes with ALT. Pierisgilli et al. [15] reported successful catheter preservation in 11 of 13 neonates (84.6%) treated with antimicrobial lock therapy for CRBSI, particularly in cases where catheter removal posed a significant clinical risk. In contrast, adult data suggest that while ALT is effective in catheter salvage, it may be associated with higher relapse rates. In a large retrospective cohort study, Ranganath et al. [16] reported microbiological relapse within 90 days in 20% of patients treated with ALT compared with 7% in those undergoing catheter removal, despite similar composite outcomes. This finding highlights the importance of careful patient selection and close follow-up when ALT is preferred over catheter removal. Overall, the 70.21% ALT success rate observed in our pediatric hemato-oncology cohort is consistent with previously reported pediatric and neonatal studies and supports the role of ALT as a viable catheter salvage strategy when catheter removal is clinically challenging or undesirable. In the present study, the overall catheter removal rate was 37.7% (20/53). Of these patients, 11.3% (n = 6) underwent immediate catheter removal without prior administration of antibiotic lock therapy (ALT), whereas catheter removal was required in 26.4% (n = 14) despite the implementation of ALT. These findings suggest that although ALT enabled catheter preservation in a considerable proportion of patients, catheter salvage was not achievable in all cases. A notable difference was observed in the distribution of causative pathogens between patients who underwent immediate catheter removal and those in whom catheter removal was necessary despite ALT. Among the six patients who underwent direct catheter removal without ALT, Klebsiella pneumoniae was identified in four cases, while methicillin-resistant coagulase-negative staphylococci (MRCoNS) were isolated in two cases. The predominance of K. pneumoniae in this subgroup is clinically meaningful, as Gram-negative bloodstream infections have been consistently associated with more severe clinical presentations and a reduced likelihood of successful catheter salvage. Both pediatric and adult studies have reported that Gram-negative pathogens frequently prompt early catheter removal due to concerns regarding rapid clinical deterioration and relapse, even when ALT is considered as a salvage strategy [17, 18]. In contrast, among the 14 patients who required catheter removal despite ALT, infections were caused by a combination of Gram-positive and Gram-negative microorganisms. This finding indicates that ALT failure cannot be attributed solely to pathogen type and suggests that additional factors may influence catheter salvage outcomes. Similar patterns have been described in pediatric oncology and hematology populations. In a retrospective study, De Frutos Porras et al. [13] reported that although adjunctive ALT significantly decreased catheter removal rates, catheter removal remained necessary in a subset of patients due to persistent clinical symptoms, local catheter-site infection, or infectious relapse. Likewise, Signorino et al. [12] demonstrated that despite overall favorable outcomes with ALT in children, treatment failure leading to catheter removal occurred in selected cases. Pathogen-focused pediatric evidence further supports these observations. In children with coagulase-negative staphylococcal central line–associated bloodstream infections, Ergenç et al. [14] reported satisfactory catheter salvage rates with ALT; however, catheter loss was associated with persistent bacteremia and younger age, underscoring the importance of host-related and infection-related factors beyond microbial etiology alone. Adult data provide additional context, as Ranganath et al. [16] showed that although ALT reduced the need for immediate catheter removal, it was associated with a higher risk of microbiological relapse than catheter removal, underscoring the need for careful patient selection and close clinical monitoring when catheter salvage strategies are employed. These findings indicate that ALT represents an effective catheter-preserving approach in a substantial proportion of pediatric hemato-oncology patients; however, early catheter removal may remain warranted in cases involving high-risk Gram-negative pathogens such as Klebsiella pneumoniae or in the presence of inadequate clinical or microbiological response despite ALT. Therefore, ALT should be considered a selective, individualized catheter-salvage strategy rather than a universal alternative to catheter removal. In our study, the CRBSI rate was 12.79 per 1,000 catheter-days, indicating a relatively high infection burden in pediatric hemato-oncology patients. Although direct comparisons across studies are challenging due to differences in patient populations and catheter management practices, previous pediatric hemato-oncology studies have similarly emphasized that this group is particularly high-risk for catheter-related infections [12, 13]. Prolonged catheter exposure, intensive chemotherapy, immunosuppression, and frequent catheter manipulation have been cited as key contributors to elevated infection rates in this setting [18]. A notable finding of our study is that, irrespective of catheter type, the period from days 11 to 45 following catheter insertion was associated with the highest risk of CRBSI. This observation is consistent with previous reports indicating that catheter-related infections frequently occur during the early post-insertion phase, when biofilm formation and repeated catheter access are most prominent [18]. In pediatric cohorts, early catheter use has been identified as a critical vulnerability window during which preventive measures and close monitoring are particularly important [12]. Supporting this temporal pattern, the median time to infection in our study was 30 days, aligning closely with the high-risk interval identified. Similar findings have been reported in pediatric oncology and hematology populations, where CRBSI tend to occur within the first weeks following catheter insertion rather than during long-term catheter dwell [13]. These data suggest that infection risk is not solely related to catheter duration but is also strongly influenced by early catheter-related factors, including insertion technique, early handling practices, and host vulnerability. Our findings reinforce the evidence that pediatric hemato-oncology patients experience a substantial risk of CRBSI early after catheter placement. Identifying the 11–45 day post-insertion period as a peak risk interval has important clinical implications, as it highlights a critical window for intensified surveillance, strict adherence to catheter care protocols, and timely preventive or therapeutic interventions aimed at reducing infection-related morbidity [12, 18]. In our study, ALL was found to be significantly associated with CRBSI, highlighting the increased infection risk of this diagnostic group [12, 13]. Children with ALL are frequently exposed to intensive chemotherapy protocols, prolonged immunosuppression, and repeated catheter manipulation, all of which have been previously associated with an increased risk of catheter-related infections [18]. In addition, neutropenia was independently associated with CRBSI in our cohort, underscoring the critical role of impaired host immune defenses in the pathogenesis of catheter-related infections [12, 18]. The observed predilection for Gram-negative infections in neutropenic patients may partly explain the higher rate of ALT failure in this subgroup. Gram-negative organisms, particularly Klebsiella pneumoniae, are known to produce dense, structurally complex biofilms that are markedly less susceptible to antibiotic penetration compared with those formed by Gram-positive cocci [18]. Furthermore, the inherent virulence of Gram-negative pathogens, including rapid clinical deterioration, endotoxin-mediated sepsis, and a higher propensity for intraluminal persistence, may render catheter salvage strategies ineffective even when high-concentration antibiotic lock solutions are employed. In neutropenic patients, the absence of adequate immune-mediated bacterial clearance further compounds this challenge, as the host is unable to eradicate residual organisms not eliminated by the antibiotic lock [13, 18]. These factors collectively suggest that neutropenic patients with Gram-negative CRBSI represent a particularly high-risk subgroup in whom early catheter removal should be strongly considered rather than deferred pending ALT response. Similarly, fever was significantly associated with CRBSI in our study, reinforcing its role as a key clinical indicator of bloodstream infection in pediatric oncology patients [12]. Fever in immunocompromised children with central venous catheters has been widely recognized as an early manifestation of systemic infection and often prompts evaluation for catheter-related sources [18]. These findings suggest that CRBSI risk in pediatric hemato-oncology patients is influenced by a combination of underlying diagnosis (ALL), hematological status (neutropenia), and clinical presentation (fever), rather than by a single determinant alone [12, 13]. Moreover, the observed association between neutropenia and Gram-negative infections underscores the importance of pathogen-specific, risk-adapted management strategies in this vulnerable population [18–20]. Conclusion In this retrospective single-center study, 70 CRBSI episodes were identified among 53 pediatric hemato-oncology patients, corresponding to an incidence of 12.79 per 1,000 catheter-days. ALT was successful in 70.21% of patients who received the intervention (33/47), and ALT use was significantly associated with catheter retention. Despite this, the overall catheter removal rate remained 37.7%, including 11.3% removed without ALT and 26.4% removed despite ALT. The median time to infection was 30 days. Microbiologically, CoNS were the most frequent isolates, followed by gram-positive bacilli and Klebsiella spp., and gram-negative infections were more frequently associated with neutropenia. These findings support several clinically actionable implications. First, given the 11–45 day high-risk window, intensified preventive bundles and surveillance should be prioritized immediately after catheter insertion, including strict hub disinfection, minimizing line access, reinforcing dressing integrity, and targeted staff reminders during this interval. Second, ALT appears to be a pragmatic catheter-salvage strategy in appropriately selected patients; therefore, early consideration of ALT alongside systemic antibiotics is recommended when catheter preservation is clinically desirable, and there is no indication for immediate removal. Third, because catheter removal without ALT in our cohort was predominantly observed with Klebsiella spp. and MRCoNS, prompt risk stratification by suspected/confirmed pathogen and clinical status is essential, with lower thresholds for early catheter removal when high-risk organisms or poor clinical response are present. Finally, the observed association between gram-negative infection and neutropenia underscores the need for pathogen-informed, risk-adapted management, particularly in neutropenic patients, integrating rapid microbiological diagnostics, timely antimicrobial optimization, and close monitoring for treatment failure. Prospective multicenter studies with standardized ALT protocols and longitudinal follow-up are warranted to further refine patient selection, optimize protocol parameters, and evaluate relapse and longer-term outcomes. Acknowledgements We are grateful to all healthcare professionals in the pediatric hematology and oncology clinic who facilitated the conduct of this study. Abbreviations Antibiotic Lock Therapy Absolute Neutrophil Count Analysis of Variance Bone Marrow Transplantation Central Line–Associated Bloodstream Infection Coagulase-Negative Staphylococci Catheter-Related Bloodstream Infection Central Venous Catheter / Central Venous Catheters Global Quality Scale Infectious Diseases Society of America Interquartile Range Methicillin-Resistant Coagulase-Negative Staphylococci Statistical Package for the Social Sciences Total Parenteral Nutrition Authors’ contributions B.K., R.S.Ş., P.T., and G.E. contributed to the conceptualization and design of the study. Methodology was developed by B.K., R.S.Ş., P.T., G.E., and S.K. Investigation and data collection were conducted by B.K., P.T., G.E., S.K., Z.K., and G.T., while data curation was performed by B.K., P.T., and G.E. Formal analysis was carried out by B.K. and R.S.Ş. Resources required for the study were provided by S.K., Z.K., A.S., S.H., and G.T. Supervision of the research process was undertaken by R.S.Ş., A.S., and Z.K. The original draft of the manuscript was prepared by B.K. and R.S.Ş. All authors contributed to reviewing and editing the manuscript, approved the final version, and agreed to be accountable for all aspects of the work **.**. Funding None. Data availability The datasets generated and/or analysed during the current study are not publicly available due to ethical restrictions protecting participant confidentiality but are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This retrospective study was approved by the Ethics Committee of Istanbul University, Istanbul Faculty of Medicine (Decision No: 10; Date: 24/05/2024). Ethics Committee of Istanbul University also waived the requirement for informed consent to participate, given the retrospective design of the study and the use of anonymized patient records. No direct patient contact or intervention was involved, as data were collected solely through a review of existing medical records. All procedures were carried out in accordance with institutional ethical standards and the principles of confidentiality. Consent for publication None. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Remziye Semerci Şahin, Email: rsemerci@ku.edu.tr. Gülşah Tanyıldız, Email: gulsahtanyildiz@istanbul.edu.tr. References Associated Data Data Availability Statement The datasets generated and/or analysed during the current study are not publicly available due to ethical restrictions protecting participant confidentiality but are available from the corresponding author on reasonable request.